NEW CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE

The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical...

Full description

Saved in:
Bibliographic Details
Main Authors CANDIANI, Ilaria, OTTAIANO, Giovanni, TOMASI, Attilio
Format Patent
LanguageEnglish
French
Published 30.11.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it. La présente invention concerne une nouvelle forme cristalline de N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-méthyl-pipérazin-1-yl)-2-(tétrahydro-pyran-4-ylamino)-benzamide, son procédé de préparation, son utilité dans le traitement de maladies provoquées par une activité de protéine kinase dérégulée et des compositions pharmaceutiques le contenant.
Bibliography:Application Number: WO2017EP61919